The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,…
Laura Soucek
This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology…
Dr. Jonathan Whitfield and Dr. Mariano Zacarías-Fluck, researchers in the Models of Cancer Therapies Group at VHIO, together with Dr….
Laura Soucek, an ICREA Research Professor, Director of VHIO’s Experimental Therapeutics Program, and Head of our Models of Cancer Therapies…
Peptomyc, the VHIO and ICREA spin-off co-founded and directed by Dr. Laura Soucek, ICREA professor and director of the VHIO…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
The biotech company Peptomyc SL announced today that it has been awarded €5 million blended financing from the Horizon Europe,…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Published in the journal Genes & Development*, results of a study led by Laura Soucek, co-Director of the Vall d’Hebron…
